ADMA Biologics Successfully Implements Innovative AI Program, Named ADMAlytics

Rhea-AI Summary

ADMA Biologics, Inc. successfully implements ADMAlytics, an AI program combining AI and machine learning to optimize production processes. The company achieved efficiency improvements in commercial production through automation, with broader implementation expected to enhance efficiencies across the organization.

Insights

Biopharmaceutical Industry Analyst

The introduction of ADMAlytics by ADMA Biologics represents a significant advancement in the biopharmaceutical manufacturing space. By leveraging generative AI and machine learning, ADMA is positioned to enhance production efficiency, particularly in plasma pooling for its ASCENIV™ product. This innovation is likely to reduce production costs and time, directly impacting the company's bottom line.

As the industry moves towards more personalized medicine, the ability to streamline production processes becomes increasingly valuable. The use of AI to predict outcomes and automate processes could set a new standard for operational efficiency in the sector. This technology could lead to a competitive advantage for ADMA, as it may increase the speed at which products can be brought to market while maintaining high quality standards.

Investors should monitor the broader implementation of ADMAlytics across the company's supply chain and production operations. Success in these areas could signal a positive shift in the company's earnings growth trajectory, potentially affecting stock performance positively. Moreover, the industry-wide implications of such technological advancements could drive a trend of increased investment in AI across the biopharmaceutical sector.

Healthcare Technology Analyst

The deployment of ADMAlytics by ADMA Biologics underscores the growing intersection between technology and healthcare, particularly in the field of immunotechnology. The ability to prospectively automate and improve efficiency in commercial production is a testament to the transformative potential of AI in healthcare.

From a technology perspective, the integration of AI into production processes is expected to lead to better resource allocation, reduced waste and enhanced product consistency. This can be especially critical in the production of specialty biologics, where precision and reliability are paramount. The potential for AI to mitigate risks associated with batch variability and supply chain disruptions could translate into more stable product availability for patients.

Stakeholders, including healthcare providers and patients, may benefit from the increased reliability and efficiency that AI-driven processes promise. For investors, the key metric to watch will be the actual performance indicators post-implementation, such as reduced production times, cost savings and the impact on the company's market share within the specialty biologics space.

Supply Chain Management Expert

ADMAlytics' expected impact on ADMA Biologics' supply chain and production operations could be a game-changer for the company's operational logistics. By optimizing the plasma pooling process, which is a critical step in the production of ASCENIV™, ADMAlytics has the potential to streamline the supply chain, leading to faster throughput and reduced inventory holding costs.

The ability to rapidly implement efficiencies across the organization could also result in improved responsiveness to market demand and better management of raw materials and finished goods. This level of supply chain agility is crucial in the biopharmaceutical industry, where product life cycles can be short and demand can fluctuate unpredictably.

For stakeholders, the anticipated improvements in supply chain management could mean a more robust and resilient operation capable of withstanding external pressures such as raw material shortages or increased demand. Long-term, the adoption of such technologies could redefine supply chain excellence in the biopharmaceutical industry and provide a blueprint for other companies to follow.

ADMAlytics Combines Generative AI and Machine Learning to Optimize Production Processes

ADMA Successfully Utilized ADMAlytics’ New Capabilities for the First Time to Automate and Realize Efficiency Improvements for Commercial Production Plasma Pooling

Broader Implementation of ADMAlytics Expected to Provide Efficiencies Across the Organization

RAMSEY, N.J. and BOCA RATON, Fla., Feb. 21, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced the successful initial use of its Artificial Intelligence (“AI”) program, named ADMAlytics. ADMAlytics combines AI and machine learning to improve and predict outcomes for production and operational processes. Recently, ADMA successfully produced its first batch of ASCENIV™ utilizing this innovative ADMAlytics software to prospectively automate and realize efficiency improvements to plasma pooling during commercial manufacturing. ADMA expects broad implementation of the new ADMAlytics capabilities has the potential to provide for rapid realization of efficiencies across the Company’s supply chain and production operations.

“We're proud to announce the successful development and implementation of our innovative ADMAlytics AI program,” said Adam Grossman, President and Chief Executive Officer of ADMA. “This achievement aligns seamlessly with our overarching mission to continuously innovate our production processes for specialty biologics, while also building on our reputation as a thought leader within the commercial specialty biologics markets for the patients our therapies serve.”

Mr. Grossman continued, “The robust ADMAlytics AI program is designed to optimize and streamline our intricate production processes, delivering significant efficiencies throughout the organization. In the complex landscape of specialty biologics production, maintaining uninterrupted operations is paramount, and we believe that ADMAlytics will further bolster our commitment to ensuring continuity of patient care. We anticipate the program's rollout across the entirety of the ADMA organization will, in due course, bring far reaching improvements and efficiencies across our operations and further support the Company’s earnings growth trajectory. We applaud our internal Information Technology team for their execution and success bringing this innovative software to commercial readiness and real-world application. ADMAlytics is another testament to our commitment to lead a new age of immunotechnology for specialty biologics.”

About ADMA Biologics, Inc. (ADMA)

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM^® (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of PI; and NABI-HB^® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty biologics, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA holds numerous U.S. and foreign patents related to and encompassing various aspects of its products and product candidates. For more information, please visit www.admabiologics.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. (“we,” “our” or the “Company”). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain such words as “estimate,” “project,” “intend,” “forecast,” “target,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will,” “is likely,” “will likely,” “should,” “could,” “would,” “may,” or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements include, but are not limited to, statements about the Company’s ADMAlytics program, its application and its impact on the Company’s patients, operations and financial performance. Actual events or results may differ materially from those described in this press release due to a number of important factors. Current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements. Forward-looking statements are subject to many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events, to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, the risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.

COMPANY CONTACT:
Skyler Bloom
Senior Director, Business Development & Corporate Strategy | 201-478-5552 |sbloom@admabio.com

INVESTOR RELATIONS CONTACT:
Michelle Pappanastos
Senior Managing Director, Argot Partners | 212-600-1902 | michelle@argotpartners.com

FAQ

How did ADMA Biologics improve production processes?

ADMA successfully utilized ADMAlytics, an AI program combining AI and machine learning, to automate and realize efficiency improvements for commercial production.

What was the first product successfully produced using ADMAlytics?

The first batch of ASCENIV™ was successfully produced using the innovative ADMAlytics software.

What are the expected benefits of broader implementation of ADMAlytics?

Broader implementation of ADMAlytics is expected to provide efficiencies across the organization's supply chain and production operations.

Who is the President and CEO of ADMA Biologics?

Adam Grossman is the President and Chief Executive Officer of ADMA Biologics.

What is the ticker symbol for ADMA Biologics?

The ticker symbol for ADMA Biologics is ADMA.